

Diabetes treatment-related quality of life is associated with levels of self-care activities in insulin injection among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 8)

Tsuyoshi Mashitani · Yasuaki Hayashino · Shintaro Okamura ·
Masako Kitatani · Miyuki Furuya · Tadao Iburi ·
Hirohito Kuwata · Satoru Tsujii · Hitoshi Ishii

Received: 16 December 2014 / Accepted: 6 February 2015 / Published online: 19 February 2015
© Springer-Verlag Italia 2015

Abstract

Aims We investigated the association between diabetes treatment-related quality of life (QOL) and levels of self-care activities in insulin injection among Japanese patients with type 2 diabetes.

Methods Data from 1394 patients with type 2 diabetes on insulin therapy were obtained from a diabetes registry in Japan. We used the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire and relative risk regression analysis to assess the independent association of high levels of self-care activities in insulin injection and DTR-QOL scores while adjusting for possible confounders.

Results The mean age, BMI and HbA1c level were 65.8 years, 24.8 kg/m² and 62 mmol/mol (7.8 %), respectively. The frequency of insulin injection omission was associated with DTR-QOL scores. In the multivariable-adjusted model, the relative risks for high levels of self-care activities in insulin injection was 1.15 (95 % confidence interval, 1.05–1.26) in the highest quintile compared with those in the lowest quintile of DTR-QOL scores.

Subgroup analysis confirmed this association in patients <65 years.

Conclusions DTR-QOL was associated with self-reported levels of self-care activities in insulin injection, particularly among Japanese patients <65 years with type 2 diabetes. DTR-QOL might be a useful tool to identify patients who consequently omit insulin. For patients with low DTR-QOL score, healthcare providers should discuss their treatment-related problems to prevent insulin injection omission.

Keywords Insulin · Self-care activities · Omission · Quality of life

Introduction

Because the progressive impairment of insulin secretion is characteristic of type 2 diabetes [1], guidelines issued by the American Diabetes Association and National Institute for Health and Clinical Excellence (NICE) state that insulin is the most effective glucose-lowering agent and insulin therapy is a key component of effective diabetes management over the course of the disease [2–4].

In a clinical setting, insulin therapy may not achieve optimal outcomes [5]. The Japan Diabetes Clinical Data Management Study, a multicenter study of diabetes in Japan, showed that the average HbA1c level of patients receiving insulin was 66 mmol/mol (8.0 %) and only 20.9 % of these achieved a HbA1c level of <55.9 mmol/mol (7.0 %) [6]. Health-related quality of life (HRQOL) is one of the important factors that should influence glycemic control in the insulin-treated patients with diabetes [7]. Diabetes itself leads to worse HRQOL in patients with acute coronary syndrome treated with coronary angioplasty

Managed by Antonio Secchi.

For the Diabetes Distress and Care Registry at Tenri Study Group.

Diabetes Distress and Care Registry at Tenri Study Group are listed in the [Appendix](#).

T. Mashitani (✉) · H. Ishii
Department of Diabetology, Nara Medical University,
840 Shijo-cho, Kashihara City, Nara 634-8552, Japan
e-mail: mashiyana@gmail.com

Y. Hayashino · S. Okamura · M. Kitatani · M. Furuya ·
T. Iburi · H. Kuwata · S. Tsujii
Department of Endocrinology, Tenri Hospital, Tenri,
Nara 632-8552, Japan

[8]. Recently, several studies investigated what factors had an impact on HRQOL in patients with type 1 and type 2 diabetes. Younger age (<40 years) at type 2 diabetes diagnosis was significantly associated with a poor diabetes-related QOL: specific life domains such as freedom to eat and drink [9]. Onset of type 1 diabetes during the first 5 years of life may result in better QOL and less fatalism in the long term as these patients are presumed to have no memory of disease onset, which could reduce trauma and facilitate adaptation to managing life with diabetes. [10]. Continuous subcutaneous insulin infusion (CSII) confers significant advantages in terms of HRQOL with improvements in treatment satisfaction, perceived clinical efficacy and reduction in treatment interference with daily activities [11]. The continuous glucose monitoring on CSII resulted in better metabolic control without imposing an additional burden on the patient [12]. Inadequate adherence to insulin injections is associated with higher HbA1c levels [13, 14]. Therefore, it is important that physicians pay close attention to HRQOL and problems that interfere with adherence to insulin injection and solve these problems with the patient to achieve good glycemic control.

Although there were several questionnaires developed to assess patient perceptions of insulin therapy that could affect insulin adherence [13, 15–20], few of these studies assessed the association between the factors that could affect insulin adherence and levels of self-care activities in insulin injection in other than Western countries. A recent study found that insulin injection-related problems such as interference with daily activities, injection pain and embarrassment were independent risk factors for insulin omission [21]. However, the study did not quantify the patient perceptions associated with the treatment-related problems.

The objective of the present study was to explore the association between patient perceptions of insulin therapy quantified by diabetes therapy-related quality of life (DTR-QOL) and levels of self-care activities in insulin injection in patients with type 2 diabetes using a large-scale single-center registry in Japan. We further hypothesized that DTR-QOL scores associated with levels of self-care activities in insulin injection affected mainly younger patients because older patients appeared to adhere better to daily self-care regimens.

Subject, materials and methods

Patients

Patient data were derived from the second-year survey using a diabetes registry maintained by the Tenri Hospital, a regional tertiary-care teaching hospital in Tenri, Nara,

Japan. The details of this registry have been published elsewhere [22, 23]. In brief, the present study included patients with diabetes who were recruited from the registry and visited the outpatient clinic of our hospital from October 2009 to December 2011. The second-year survey was performed from January to December 2011. We excluded patients with pre-diabetes diagnosed by an oral glucose tolerance test, gestational diabetes, type 1 diabetes, diabetes induced by the use of steroids or other endocrinological diseases and finally used the data of patients diagnosed with type 2 diabetes. The Ethics Committee of Tenri Hospital approved this study. Informed consent was obtained from the patients prior to the start of study.

Data collection

Trained clinical research coordinators collected patient demographics from medical charts, which included age, gender, body weight, duration of diabetes, past medical history (micro- and macro-vascular complications) and treatment modalities. On the day of questionnaire distribution, HbA1c values were assessed and expressed as National Glycohemoglobin Standardization Program equivalent values [24]. The presence of depressive symptoms at the time of participation in this study was made using the Patient Health Questionnaire-9 as a screening tool [25]. Influence of diabetes treatment on patient QOL was measured by the DTR-QOL questionnaire [26] with 29 items, rated using a 7-point Likert scale (1: strongly agree to 7: strongly disagree), constituting four domain structures ('burden on social activities and daily activities,' 'anxiety and dissatisfaction with treatment,' 'hypoglycemia' and 'satisfaction with treatment'). The score of each item was reversed so that 7 represented the highest QOL score. The total score was converted to 0–100 (best-case response 100; worst case response 0). High DTR-QOL score means good QOL for their diabetes treatment. Physical exercise was measured using a short version of the International Physical Activity Questionnaire (IPAQ), a self-reported instrument, which asks for an estimate of total weekly physical activity (walking/vigorous and moderate-intensity activity) during the previous week. The total Metabolic Equivalent of Task (MET) score was calculated by weighting the minutes reported for each activity per week using a MET energy expenditure estimate that was assigned to each category (low, moderate and high), following the IPAQ scoring criteria [27].

Outcome variables

We assessed levels of self-care activities in insulin injection to scheduled insulin regimen using the response to the following questionnaire: 'Do you have insulin shots as

scheduled?’ (response options: 1 = always, 2 = largely, 3 = more than half of the time, 4 = not always and 5 = no). Those who responded ‘always’ were defined as high levels of self-care activities in insulin injection.

Statistical analysis

Data from patients with type 2 diabetes who were under any type of insulin regimen were included in the current analysis. Continuous variables are reported as the mean and SD or interquartile ranges, where indicated. Differences between groups were evaluated by the trend test. Relative risk regression analyses were used to estimate the relative risks (95 % CI) for high levels of self-care activities in insulin injection in comparison with a reference category of the lowest quartile of DTR-QOL scores. Three statistical models were used; the first was a crude model and the second was adjusted for age and gender (model 1) and the third was adjusted for variables in model 1 plus BMI, duration of diabetes, daily insulin injection frequency, the presence of depressive symptoms and HbA1c levels (model 2). We selected these covariates, because these were considered to be associated with levels of self-care activities in insulin injection.

Next, we evaluated the association between the DTR-QOL quartiles and high levels of self-care activities in insulin injection when stratified by age (<65 and \geq 65 years) using a multivariable-adjusted relative risk regression model. Furthermore, we evaluated the relative risks for high levels of self-care activities in insulin injection among the quartiles of DTR-QOL subdomain scores with the lowest quartile as a reference (‘burden on social activities and daily activities,’ ‘anxiety and dissatisfaction with treatment,’ ‘hypoglycemia’ and ‘satisfaction with treatment’) stratified by age (<65 and \geq 65 years).

All probability (*p*)-values were two sided and those <0.05 were considered statistically significant. All analyses were performed using Stata/SE statistical software version 12.0 (Stata Corporation, College Station, TX, USA).

Results

Patient characteristics

Of all the 4330 eligible patients with diabetes [mean age (SD), 65.6 (12.1); 40.5 % female; 4.6 % with type 1 diabetes; 92.3 % with type 2 diabetes], 4191 provided consent to participate in the study, of whom 3717 were confirmed with type 2 diabetes and 1402 were treated with insulin during the study period. All of them used pen-type insulin injections. We further excluded eight patients who failed to

complete the DTR-QOL questionnaire. The remaining 1394 patients met the inclusion criteria.

Table 1 shows characteristics of the patients according to levels of self-care activities in insulin injection. Overall, the mean age of the eligible patients was 65.8 years, with a mean BMI of 24.8 kg/m² and a mean number of daily insulin injections of 2.4. One thousand and seventy-six patients (77.2 % of the total) reported they always injected their prescribed insulin and 20.7 (*n* = 288), 1.8 (*n* = 25) and 0.4 % (*n* = 5) largely, more than half of time and not always injected their prescribed insulin, respectively. None of them reported they never injected prescribed insulin. Older patients (*p* < 0.001), those who had a longer duration of diabetes (*p* < 0.001), those with lower HbA1c levels (*p* < 0.001), higher DTR-QOL scores (*p* < 0.001) and those with cardiovascular diseases (*p* = 0.003) were less likely to omit insulin injections, whereas those who took more injections (*p* = 0.003), current smokers (*p* < 0.001) and those with depressive symptoms (*p* = 0.029) were more likely to omit insulin injections.

The relative risks for the association between high levels of self-care activities in insulin injection and DTR-QOL quartiles are shown in Table 2. In the crude model, the relative risk for high levels of self-care activities in insulin injection was 1.37 (95 % CI, 1.26–1.49) in the highest DTR-QOL quartile group compared with that of the reference category of the lowest DTR-QOL quartile. We observed a statistically significant linear trend across all DTR-QOL categories (*p* < 0.001). This association was observed after adjusting for other possible confounders, including age and gender (model 1; *p* < 0.001), and the variables in model 1 plus BMI, duration of diabetes, daily insulin injection frequency, the presence of depressive symptoms and HbA1c level (model 2; *p* = 0.002).

Results of multivariable-adjusted relative risk regression analysis stratified by age are shown in Table 3. In patients <65 years of age, the relative risks of those in the 2nd, 3rd and 4th quartile for high levels of self-care activities in insulin injection compared with that of those in the 1st quartile of DTR-QOL scores were 1.27 (95 % CI, 1.07–1.51), 1.32 (95 % CI, 1.11–1.58) and 1.35 (95 % CI, 1.12–1.63), respectively, and we observed a significant trend across all categories (*p* = 0.001). However, we did not observe significant associations among the patients aged \geq 65 years after adjusting for multi-variables.

Next, we evaluated the association between high levels of self-care activities in insulin injection and the DTR-QOL subdomain scores stratified by age. As shown in Table 4, higher scores on the ‘hypoglycemia’ domain of DTR-QOL were significantly associated with high levels of self-care activities in insulin injection in both age categories. However, we observed significant associations between high levels of self-care activities in insulin injection

Table 1 Patient characteristics according to levels of self-care activities in insulin injection

Answer to the questionnaire	Total <i>n</i> = 1394	Always <i>n</i> = 1076	Largely <i>n</i> = 288	More than half of time <i>n</i> = 25	Not always <i>n</i> = 5	<i>p</i> value
Age (years)	65.8 (11.8)	67.7 (10.3)	60.8 (13.3)	46.8 (15.7)	46 (10.6)	<0.001
Female (%)	41.3	42.4	37.2	40.0	60.0	0.280
BMI (kg/m ²)	24.8 (4.2)	24.7 (4.1)	25.0 (4.5)	27.7 (6.8)	22.6 (6.3)	0.160
Duration (years)	18.5 (10.5)	19.2 (10.7)	16.7 (9.9)	12.1 (7.4)	12.8 (9.4)	<0.001
HbA1c (%)	7.8 (1.3)	7.7 (1.2)	8.1 (1.5)	9.3 (1.7)	8.5 (2.3)	<0.001
HbA1c (mmol/mol)	61.6 (14.2)	60.2 (13.1)	65.2 (16.2)	78.3 (18.8)	69.1 (24.7)	
Daily insulin injection frequency	2.4 (0.9)	2.3 (0.9)	2.6 (0.9)	2.4 (1.0)	2.6 (1.1)	<0.001
Prescribed insulin units per day	31.1 (18.7)	30.8 (18.9)	32.1 (17.8)	33.2 (17.9)	19.3 (8.1)	0.218
DTR-QOL score (IQR)	68.0 (54.0–83.3)	70.3 (56.9–85.6)	60.6 (17.8)	57.6 (18.2)	56.6 (23.1)	<0.0001
Non drinker (%)	71.6	72.5	70.0	52.0	60.0	0.057
Exercise (IPAQ category) (%)						0.679
Low	44.3	43.6	47.2	40.0	40.0	
Moderate	27.1	28.0	23.3	28.0	60.0	
High	28.6	28.4	29.5	32.0	0.0	
Nephropathy (%)	27.4	27.7	27.1	16.0	40.0	0.567
Diabetic retinopathy (%)	67.3	66.5	69.9	68.0	80.0	0.101
Past history of cancer (%)	9.7	10.3	8.0	4.0	0.0	0.093
Past history of cardio vascular disease (%)	16.9	18.3	13.5	0.0	0.0	0.003
Smoking (%)						<0.001
Never	45.0	47.4	37.5	32.0	20.0	
Past	36.6	36.9	37.2	20.0	20.0	
Current	18.5	15.7	25.4	48.0	60.0	
Non depression	94.2	94.7	87.5	80.0	5.8	0.029

Nephropathy; urine albumin/creatinine ratio >300 mg/dl or/and eGFR < 30 ml/min/1.73 m²

Table 2 Correlation between levels of self-care activities in insulin injection and DTR-QOL score

	DTR-QOL score				<i>p</i> for trend
	1st quartile <i>n</i> = 361	2nd quartile <i>n</i> = 345	3rd quartile <i>n</i> = 343	4th quartile <i>n</i> = 345	
Range	6.9–54.0	54.6–69.5	70.1–83.3	83.9–100	
Relative risks for never insulin injection omission (crude)	Reference	1.15 (1.04–1.27)	1.25 (1.15–1.37)	1.37 (1.26–1.49)	<0.001
Relative risk for never insulin injection omission (model 1)	Reference	1.12 (1.02–1.23)	1.17 (1.07–1.28)	1.24 (1.14–1.34)	<0.001
Relative risk for never insulin injection omission (model 2)	Reference	1.09 (0.98–1.20)	1.11 (1.01–1.22)	1.15 (1.05–1.26)	0.002

RR relative risk

Model 1 adjusted for age and gender

Model 2 adjusted for the variables in model 1, BMI, duration of diabetes, depression symptoms, HbA1c and daily insulin injection frequency

and other domains, such as ‘burden on social activities and daily activities,’ ‘anxiety and dissatisfaction with treatment’ and ‘satisfaction with treatment’ only in the younger age category.

Discussion

To the best of our knowledge, this is the first cross-sectional study to focus on the association between the

Table 3 Correlation between levels of self-care activities in insulin injection and DTR-QOL score quartile stratified by age

	DTR-QOL				<i>p</i> for trend
	1st quartile	2nd quartile	3rd quartile	4th quartile	
RRs for no insulin injection omission stratified by age					
Gender-adjusted model (age < 65)	Reference	1.33 (1.13–1.57)	1.42 (1.20–1.68)	1.52 (1.29–1.79)	<0.001
Gender-adjusted model (age ≥ 65)	Reference	0.97 (0.87–1.08)	1.04 (0.95–1.14)	1.13 (1.04–1.23)	0.003
Model 1 ^a					
Multivariable-adjusted model (age < 65)	Reference	1.27 (1.07–1.51)	1.32 (1.11–1.58)	1.35 (1.12–1.63)	0.001
Multivariable-adjusted model (age ≥ 65)	Reference	0.94 (0.84–1.06)	1.00 (0.90–1.10)	1.07 (0.97–1.17)	0.034

^a Model 1 adjusted for gender, BMI, duration of diabetes, depression symptoms, HbA1c and daily insulin injection frequency

patient's perception about diabetes treatment quantified by DTR-QOL questionnaire and levels of self-care activities using a large sample of patients with type 2 diabetes. We found for the first time that DTR-QOL scores were significantly associated with self-reported levels of self-care activities in insulin injection, and better diabetes-specific health-related QOL was associated with higher levels of self-care activities in insulin injection among Japanese patients with type 2 diabetes, independent of possible confounders. We also observed that this association varied depending on patient characteristics and may be applicable only to patients aged <65 years. Our results showed that diabetes therapy-related QOL, as quantified by DTR-QOL questionnaire, is an important measure that may probe into levels of self-care activities in insulin injection in Japanese clinical settings. Healthcare providers should pay close attention to the treatment-related QOL of relatively young patients treated with insulin therapy because poor glycemic control may result from insufficient adherence to insulin injection schedules.

Peyrot et al. [21] reported that >25 % of patients in their internet survey of 501 patients with diabetes treated by insulin responded that insulin injections interfered with daily activities and had a major or moderate impact on QOL. Many factors have been suggested to impact on QOL of daily activities, such as age, gender, diabetic complications [28], complexity of treatment regimens [29] and symptoms of depression [30]. Cramer et al. [31] reported that adherence to an insulin regimen varied from 62 to 64 % in patients with type 2 diabetes in developed countries. Therefore, the identification of factors associated with non-adherence to insulin therapy is essential to prevent diabetic complications. Davies et al. [32] reviewed real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes and identified the following factors associated with non-adherence: patient-perceived barriers to adherence, type of delivery device and cost of medication. Furthermore, they identified that age and female gender were predictive factors of non-adherence as well as traveling, dislike of injections,

embarrassment because of injections, challenging social conditions and stress or emotional problems were patient-perceived barriers to adherence. They also identified that changing to insulin administration by a pen device instead of a vial or syringe and an insurance scheme, in which a co-payment system reduced the cost of medication, would improve adherence to insulin injection. Ishii et al. [7] reported that the improvement in patient convenience obtained by switching from regular insulin to insulin lispro provided better adherence with insulin injection timing and improved QOL, as measured by the diabetes therapy-related QOL questionnaire. The timing of insulin injections appears to be a primary factor associated with better adherence to insulin injection. However, the previous studies did not quantify what factors affected patient QOL associated with insulin injection adherence. In our cross-sectional study, we also found that self-reported levels of self-care activities in insulin injection was higher in older patients with a longer duration of diabetes and lower HbA1c levels.

In this study, we used DTR-QOL to measure health-related QOL. There are various tools that are frequently used to measure health-related QOL, such as the diabetes-specific Diabetes QOL (DQOL) questionnaire [33], Audit of Diabetes-Dependent QOL (ADDQoL) [34], Short-Form 36 (SF-36) [35], EuroQoL 5-Dimension (EQ-5D) [36] and Diabetes Treatment Satisfaction Questionnaire (DTSQ) [37]. Because SF-36 and EQ-5D are generic instruments that are non-specific to diabetes, neither enhances our understanding of the impact of adherence to insulin injection. DQOL and ADDQoL are diabetes-specific instruments that are likely to be responsive to subgroup differences [34]. It is crucial to validate QOL questionnaires to ensure that the obtained data are meaningful. However, the Japanese version of ADDQoL has not yet been validated. Recently, Sato et al. [38] evaluated the validity and reliability of the Japanese version of DQOL. However, they did not demonstrate the validity of the questionnaire for use with Japanese patients with type 2 diabetes, particularly in domains associated with patient stress, although the reliability

Table 4 Correlation between levels of self-care activities in insulin injection and DTR-QOL subdomain quartile stratified by age category

	1st quartile	2nd quartile	3rd quartile	4th quartile	<i>p</i> for trend
Age < 65 (<i>n</i> = 596)					
Burden on social activities and daily activities (mean, IQR)	45.6 (42.3–53.8)	69.3 (64.1–74.4)	88.5 (84.6–92.3)	98.9 (97.4–100)	
RRs for full insulin adherence					
Gender-adjusted model	Reference	1.29 (1.10–1.53)	1.40 (1.19–1.64)	1.45 (1.21–1.73)	<0.001
Multivariable-adjusted model	Reference	1.21 (1.02–1.44)	1.28 (1.08–1.51)	1.30 (1.08–1.56)	0.002
Anxiety and dissatisfaction with treatment (mean, IQR)	30.3 (22.9–39.6)	51.7 (47.9–56.3)	69.2 (62.5–75.0)	91.7 (87.5–97.9)	
RRs for full insulin adherence					
Gender-adjusted model	Reference	1.22 (1.04–1.43)	1.37 (1.17–1.61)	1.39 (1.18–1.65)	<0.001
Multivariable-adjusted model	Reference	1.15 (0.97–1.35)	1.23 (1.04–1.46)	1.21 (1.01–1.46)	0.017
Satisfaction with treatment (mean, IQR)	28.5 (20.8–37.5)	49.7 (50.0–50.0)	65.3 (58.3–70.8)	89.7 (83.3–100)	
RRs for full insulin adherence					
Gender-adjusted model	Reference	1.18 (1.02–1.38)	1.21 (1.02–1.43)	1.41 (1.20–1.65)	<0.001
Multivariable-adjusted model	Reference	1.14 (0.98–1.33)	1.11 (0.94–1.31)	1.22 (1.02–1.44)	0.026
Hypoglycemia (mean, IQR)	35.7 (29.2–50.0)	65.7 (58.3–75.0)	93.7 (87.5–100)		
RRs for full insulin adherence					
Gender-adjusted model	Reference	1.14 (0.96–1.35)	1.27 (1.11–1.46)		<0.001
Multivariable-adjusted model	Reference	1.12 (0.94–1.33)	1.23 (1.07–1.42)		0.004
Age ≥ 65 (<i>n</i> = 798)					
Burden on social activities and daily activities (mean, IQR)	47.1 (42.3–53.8)	70.9 (60.3–75.6)	88.7 (84.6–92.3)	99.1 (98.7–100)	
RRs for full insulin adherence					
Gender-adjusted model	Reference	1.02 (0.92–1.13)	1.08 (0.99–1.18)	1.12 (1.03–1.23)	0.003
Multivariable-adjusted model	Reference	0.98 (0.88–1.09)	1.03 (0.94–1.14)	1.07 (0.98–1.18)	0.055
Anxiety and dissatisfaction with treatment (mean, IQR)	29.6 (25.0–37.5)	52.4 (50.0–56.25)	71.4 (64.6–77.1)	93.8 (87.5–100)	
RRs for full insulin adherence					
Gender-adjusted model	Reference	0.98 (0.88–1.09)	1.06 (0.97–1.16)	1.12 (1.03–1.21)	0.001
Multivariable-adjusted model	Reference	0.96 (0.86–1.07)	1.01 (0.92–1.11)	1.05 (0.97–1.14)	0.155
Satisfaction with treatment (mean, IQR)	28.4 (20.8–37.5)	49.9 (50.0–50.0)	67.5 (62.5–75.0)	92.7 (87.5–100)	
RRs for full insulin adherence					
Gender-adjusted model	reference	1.00 (0.91–1.10)	1.05 (0.97–1.14)	1.06 (0.97–1.15)	0.099
Multivariable-adjusted model	reference	0.99 (0.90–1.09)	1.02 (0.94–1.11)	1.02 (0.93–1.11)	0.402
Hypoglycemia (mean, IQR)	32.5 (20.8–50.0)	65.9 (62.5–75.0)	95.4 (87.5–100)		
RRs for full insulin adherence					
Gender-adjusted model	Reference	1.05 (0.96–1.16)	1.12 (1.04–1.21)		0.002
Multivariable-adjusted model	Reference	1.05 (0.95–1.16)	1.09 (1.01–1.18)		0.032

Multivariable-adjusted model adjusted for gender, BMI, duration of diabetes, depression symptoms, HbA1c and daily insulin injection frequency
IQR Inter quartile range

of the questionnaire was confirmed. DTSQ is widely used to measure therapy-related issues. While there are no universally accepted specific definitions of QOL, there is a

general consensus that QOL is multidimensional and includes physical, psychological and social aspects, which are subjective, meaning that each individual perceives

aspects of their personal lives differently [39]. Although DTSQ is widely used as a diabetes-specific questionnaire in clinical trials, it measures only treatment satisfaction, which is a relatively limited portion of QOL. The DTR-QOL questionnaire consists of the following four domains: ‘burden on social activities and daily activities,’ ‘anxiety and dissatisfaction with treatment,’ ‘hypoglycemia’ and ‘satisfaction with treatment.’ The reliability and validity of the DTR-QOL questionnaire used in this study were psychometrically evaluated using survey results obtained from 284 Japanese patients with diabetes [26]. The validity of the instrument was considered verified because DTR-QOL score was moderately correlated with that of DTSQ and the Japanese version of SF-8.

In this study, we demonstrated a positive association between health-related QOL, as measured by DTR-QOL, and levels of self-care activities in insulin injection applicable only to patients aged <65 years. We previously reported an association between self-reported high adherence to a daily insulin regimen and good glycemic control, which was also true only in the same population of relatively younger patients with type 2 diabetes on insulin therapy [14]. To explain the significant association among adherence to insulin, QOL and glycemic control observed in a limited age group shown in this study, we found that in actual clinical settings, we often experience employed patients who do not achieve good glycemic control because insulin injections were intrusive to daily activities, whereas retired patients rarely made this complaint. We observed that the subdomain of DTR-QOL ‘burden on social activities and daily activities’ was associated with levels of self-care activities in insulin injection in the patients aged <65 years but not for those aged >65 years. Our results suggest that parameters such as ‘burden on social activities and daily activities,’ ‘anxiety and dissatisfaction with treatment’ and ‘satisfaction with treatment’ are more applicable to the working-age population. Therefore, to increase patient adherence to a prescribed insulin regimen, we should increase communication with patients to discuss their problems and perception related to insulin regimen and how these problems influence their social and daily activities, particularly for patients <65 years.

The present study has several important limitations. First, there was no objective measure of insulin use, and the evaluation of levels of self-care activities in insulin injection using a simple straightforward questionnaire in this study may lead to misclassification of the patients who omit their scheduled insulin injections intentionally or accidentally. In addition, we did not evaluate the ability of self-titration of insulin dosage in each patient. Because patient-lead insulin titration allows for more frequent insulin dose titration, which can lead to better glycemic control and lifestyle flexibility than physician-lead insulin titration [40], insulin

titration method might be associated with adherence to insulin injection and HRQOL. Secondly, adherence to medication schedules may be affected by the Japanese universal health insurance system because large part of medication cost are covered and the patient does not need to pay the total expense. However, we did not address medication cost as a possible confounder in this study; therefore, cost cannot be excluded as a cofounder in the relationship between adherence and glycemic control. Finally, this study was conducted in a Japanese diabetes-specialty center, and we limited the patients to those who could visit our outpatient clinic though the strong point was the large sample of patients with type 2 diabetes treated by insulin. Because our study focused on a Japanese population, our results may not be generalized to other ethnic populations.

In conclusion, the results of this large cross-sectional sample of patients with type 2 diabetes from a diabetes registry in Japan revealed that levels of self-care activities in insulin injection were associated with DTR-QOL scores. However, this association may be applicable only to patients with diabetes aged <65 years. Healthcare provider should discuss the problems and perception about insulin treatment with patients to prevent insulin injection omission. This may lead to improved insulin adherence and consequent good glycemic control.

Acknowledgments This study was partially supported by the Manpei Suzuki Diabetes Foundation and JSPS KAKENHI (Grant Number 25460641); however, they played no role in the study design or conduct, data collection, analysis or interpretation, and the preparation, review or approval of the manuscript. We would like to especially thank Yukari Moritsuji, Yuki Fujita, Noriko Nakamura and Yoko Sakamoto (Department of Endocrinology, Tenri Hospital) for their clerical support. The authors would like to thank Enago (www.enago.jp) for the English language review.

Conflict of interest None declared for all authors.

Ethical standard This study was approved by the Institutional Ethics Committee of Tenri Hospital.

Human and Animal Rights disclosure All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent disclosure Informed consent was obtained from all patients for being included in the study.

Appendix

Members of the Diabetes Distress and Care Registry at Tenri Study Group:

Shintaro Okamura, Miyuki Furuya, Masako Kitatani, Hirohito Kuwata, Satoru Tsujii (Department of Endocrinology, Tenri Hospital); Yasuaki Hayashino (Department of Endocrinology, Tenri Hospital, Department

of Epidemiology and Healthcare Research, Kyoto University Graduate School of Medicine); Hitoshi Ishii, Tsuyoshi Mashitani (Department of Diabetology, Nara Medical University); Satoshi Matsunaga (Department of Hematology, Endocrinology and Metabolism, Niigata University); Yaeko Kondo, Naotaka Fujita (Department of Diabetes and Clinical Nutrition, Kyoto University); Rei Ueda (Second Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus), Rie Kawata (Sumire Hospital, Osaka), Masami Tanaka (Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, School of Medicine, Keio University).

References

1. U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. *Diabetes* 44(11):1249–1258
2. American Diabetes A (2012) Standards of medical care in diabetes—2012. *Diabetes Care* 35(Suppl 1):S11–S63. doi:10.2337/dc12-s011
3. NICE (2004) In: type 1 diabetes: diagnosis and management of type 1 diabetes in children and young people. National Institute for Health and Clinical Excellence: Guidance, London
4. NICE (2008) In: type 2 diabetes: national clinical guideline for management in primary and secondary care (update). National Institute for Health and Clinical Excellence: Guidance, London
5. Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, Ilkova H, Ramachandran A, Aschner P, On behalf of the IDMPs Investigators (2009) Multifaceted determinants for achieving glycemic control: the international diabetes management practice study (IDMPS). *Diabetes Care* 32(2):227–233. doi:10.2337/dc08-0435
6. Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, Takagi H, Kawai K, Japan Diabetes Clinical Data Management Study Group (2006) The status of diabetes control and antidiabetic drug therapy in Japan—a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). *Diabetes Res Clin Pract* 73(2):198–204. doi:10.1016/j.diabres.2006.01.013
7. Ishii H, Anderson JH Jr, Yamamura A, Takeuchi M, Ikeda I (2008) Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires. *Diabetes Res Clin Pract* 81(2):169–178. doi:10.1016/j.diabres.2008.03.020
8. Uchmanowicz I, Lobo-Grudzien K, Jankowska-Polanska B, Sokalski L (2013) Influence of diabetes on health-related quality of life results in patients with acute coronary syndrome treated with coronary angioplasty. *Acta Diabetol* 50(2):217–225. doi:10.1007/s00592-011-0280-2
9. Chung JO, Cho DH, Chung DJ, Chung MY (2014) An assessment of the impact of type 2 diabetes on the quality of life based on age at diabetes diagnosis. *Acta Diabetol* 51(6):1065–1072. doi:10.1007/s00592-014-0677-9
10. Trento M, Trevisan M, Coppo E, Raviolo A, Zanone MM, Cavallo F, Porta M (2014) Diagnosis of type 1 diabetes within the first five years of life influences quality of life and risk of severe hypoglycemia in adulthood. *Acta Diabetol* 51(3):509–511. doi:10.1007/s00592-013-0530-6
11. Cherubini V, Gesuita R, Bonfanti R, Franzese A, Frongia AP, Iafusco D, Iannilli A, Lombardo F, Rabbone I, Sabbion A, Salvatoni A, Scaramuzza A, Schiaffini R, Sulli N, Toni S, Tumini S, Mosca A, Carle F, Group VS (2014) Health-related quality of life and treatment preferences in adolescents with type 1 diabetes. The VIPKIDS study. *Acta Diabetol* 51(1):43–51. doi:10.1007/s00592-013-0466-x
12. Hommel E, Olsen B, Battelino T, Conget I, Schutz-Fuhrmann I, Hoogma R, Schierloh U, Sulli N, Gough H, Castaneda J, de Portu S, Bolinder J, Group SS (2014) Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study. *Acta Diabetol* 51(5):845–851. doi:10.1007/s00592-014-0598-7
13. Cramer JA, Pugh MJ (2005) The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin? *Diabetes Care* 28(1):78–83
14. Mashitani T, Hayashino Y, Okamura S, Kitatani M, Furuya M, Matsunaga S, Kuwata H, Tsujii S, Ishii H (2013) Patient-reported adherence to insulin regimen is associated with glycemic control among Japanese patients with type 2 diabetes: diabetes distress and care registry at Tenri (DDCRT 3). *Diabetes Res Clin Pract* 100(2):189–194. doi:10.1016/j.diabres.2013.03.006
15. Martinez L, Consoli SM, Monnier L, Simon D, Wong O, Yomtov B, Gueron B, Benmedjehed K, Guillemin I, Arnould B (2007) Studying the hurdles of insulin prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. *Health Qual Life Outcomes* 5:53. doi:10.1186/1477-7525-5-53
16. Snoek FJ, Skovlund SE, Pouwer F (2007) Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. *Health Qual Life Outcomes* 5:69. doi:10.1186/1477-7525-5-69
17. Mollema ED, Snoek FJ, Ader HJ, Heine RJ, van der Ploeg HM (2001) Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. *J Psychosom Res* 51(5):665–672
18. Mollema ED, Snoek FJ, Pouwer F, Heine RJ, van der Ploeg HM (2000) Diabetes fear of injecting and self-testing questionnaire: a psychometric evaluation. *Diabetes Care* 23(6):765–769
19. Peyrot M, Rubin RR (2005) Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: the insulin delivery system rating questionnaire. *Diabetes Care* 28(1):53–58
20. Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, Balkrishnan R (2004) Development and validation of the insulin treatment satisfaction questionnaire. *Clin Ther* 26(4):565–578
21. Peyrot M, Rubin RR, Kruger DF, Travis LB (2010) Correlates of insulin injection omission. *Diabetes Care* 33(2):240–245. doi:10.2337/dc09-1348
22. Hayashino Y, Tsujii S, Ishii H, Diabetes D, Care Registry at Tenri Study Group (2013) High frequency of non-nocturnal hypoglycemia was associated with poor sleep quality measure by Pittsburgh sleep quality index in patients with diabetes receiving insulin therapy: diabetes distress and care registry at Tenri (DDCRT 4). *Exp Clin Endocrinol Diabetes* 121(10):628–634. doi:10.1055/s-0033-1355424
23. Mashitani T, Hayashino Y, Okamura S, Tsujii S, Ishii H (2014) Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 5)]. *Diabetes Care* 37(1):252–258. doi:10.2337/dc13-0407
24. Dhatt GS, Agarwal MM, Bishawi B (2005) HbA1c: a comparison of NGSP with IFCC transformed values. *Clin Chim Acta* 358(1–2):81–86
25. Spitzer RL, Williams JB, Gibbon M, First MB (1992) The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. *Arch Gen Psychiatry* 49(8):624–629

26. Ishii H (2012) Development and psychometric validation of the diabetes therapy-related QOL (DTR-QOL) questionnaire. *J Med Econ* 15(3):556–563. doi:[10.3111/13696998.2012.665111](https://doi.org/10.3111/13696998.2012.665111)
27. Craig CL, Marshall AL, Sjoström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* 35(8):1381–1395. doi:[10.1249/01.MSS.0000078924.61453.FB](https://doi.org/10.1249/01.MSS.0000078924.61453.FB)
28. Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L (1997) Quality of life and associated characteristics in a large national sample of adults with diabetes. *Diabetes Care* 20(4):562–567
29. Weinberger M, Kirkman MS, Samsa GP, Cowper PA, Shortliffe EA, Simel DL, Feussner JR (1994) The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. *Med Care* 32(12):1173–1181
30. Chung JO, Cho DH, Chung DJ, Chung MY (2013) Assessment of factors associated with the quality of life in Korean type 2 diabetic patients. *Intern Med* 52(2):179–185
31. Cramer JA (2004) A systematic review of adherence with medications for diabetes. *Diabetes Care* 27(5):1218–1224
32. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R (2013) Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. *Diabet Med* 30(5):512–524. doi:[10.1111/dme.12128](https://doi.org/10.1111/dme.12128)
33. The DCCT Research Group (1988) Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). *Diabetes Care* 11(9):725–732
34. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R (1999) The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. *Qual Life Res* 8(1–2):79–91
35. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 30(6):473–483
36. EuroQol G (1990) EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy* 16(3):199–208
37. Lewis KS, Bradley C, Knight G, Boulton AJ, Ward JD (1988) A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. *Diabet Med* 5(3):235–242
38. Sato F, Mita T, Yamamoto R, Hirose T, Ito C, Tamura Y, Yokota A, Someya Y, Uchida T, Uchino H, Kawamori R, Goshō M, Ohmura C, Kanazawa A, Watada H (2013) Reliability and validity of the Japanese version of the diabetes quality-of-life questionnaire for Japanese patients with type 2 diabetes mellitus. *Diabetol Int* 5(1):21–29. doi:[10.1007/s13340-013-0125-z](https://doi.org/10.1007/s13340-013-0125-z)
39. Speight J, Reaney MD, Barnard KD (2009) Not all roads lead to Rome—a review of quality of life measurement in adults with diabetes. *Diabet Med* 26(4):315–327. doi:[10.1111/j.1464-5491.2009.02682.x](https://doi.org/10.1111/j.1464-5491.2009.02682.x)
40. Garg SK, Admane K, Freemantle N, Odawara M, Pan CY, Misra A, Jarek-Martynowa IR, Abbas-Raza S, Mirasol RC, Perfetti R (2014) Patient-led versus physician-led titration of insulin glargine in uncontrolled patients with type 2 diabetes: a randomized multinational—ATLAS study. *Endocr Pract*. doi:[10.4158/EP14079.OR](https://doi.org/10.4158/EP14079.OR)